-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
We -X- _ O
sought -X- _ O
to -X- _ O
develop -X- _ O
and -X- _ O
test -X- _ O
an -X- _ O
objective -X- _ O
scorecard-based -X- _ O
system -X- _ O
for -X- _ O
assessing -X- _ O
and -X- _ O
categorizing -X- _ O
available -X- _ O
research -X- _ O
sites -X- _ O
in -X- _ O
Lassa -X- _ O
fever-affected -X- _ O
countries -X- _ O
based -X- _ O
on -X- _ O
their -X- _ O
preparedness -X- _ O
and -X- _ O
capability -X- _ O
to -X- _ O
host -X- _ O
Lassa -X- _ B-Intervention
fever -X- _ I-Intervention
vaccine -X- _ I-Intervention
clinical -X- _ I-Intervention
trials. -X- _ I-Intervention
METHODS -X- _ O
: -X- _ O
We -X- _ O
mapped -X- _ O
available -X- _ O
clinical -X- _ B-Patient
research -X- _ I-Patient
sites -X- _ I-Patient
through -X- _ O
interrogation -X- _ O
of -X- _ O
online -X- _ O
clinical -X- _ O
trial -X- _ O
registries -X- _ O
and -X- _ O
relevant -X- _ O
disease-based -X- _ O
consortia. -X- _ O
A -X- _ O
structured -X- _ O
online -X- _ O
questionnaire -X- _ O
was -X- _ O
used -X- _ O
to -X- _ O
assess -X- _ O
the -X- _ O
capability -X- _ O
of -X- _ O
clinical -X- _ O
trial -X- _ O
sites -X- _ O
to -X- _ O
conduct -X- _ O
Lassa -X- _ B-Intervention
fever -X- _ I-Intervention
vaccine -X- _ I-Intervention
clinical -X- _ I-Intervention
trials. -X- _ I-Intervention
We -X- _ O
developed -X- _ O
a -X- _ O
new -X- _ O
scoring -X- _ O
template -X- _ O
by -X- _ O
allocating -X- _ O
scores -X- _ O
to -X- _ O
questionnaire -X- _ O
parameters -X- _ O
based -X- _ O
on -X- _ O
perceived -X- _ O
importance -X- _ O
to -X- _ O
the -X- _ O
conduct -X- _ O
of -X- _ O
clinical -X- _ O
trials -X- _ O
as -X- _ O
described -X- _ O
in -X- _ O
the -X- _ O
WHO -X- _ B-Comparison
/ -X- _ I-Comparison
TDR -X- _ I-Comparison
Global -X- _ I-Comparison
Competency -X- _ I-Comparison
Framework -X- _ I-Comparison
for -X- _ I-Comparison
Clinical -X- _ I-Comparison
Research. -X- _ I-Comparison
Cutoff -X- _ O
points -X- _ O
of -X- _ O
75 -X- _ O
% -X- _ O
and -X- _ O
50 -X- _ O
% -X- _ O
were -X- _ O
used -X- _ O
to -X- _ O
categorize -X- _ O
sites -X- _ O
into -X- _ O
categories -X- _ O
A -X- _ O
, -X- _ O
B -X- _ O
, -X- _ O
or -X- _ O
C. -X- _ O
RESULTS -X- _ O
: -X- _ O
This -X- _ O
study -X- _ O
identified -X- _ O
44 -X- _ O
clinical -X- _ O
trial -X- _ O
sites -X- _ O
in -X- _ O
8 -X- _ O
Lassa -X- _ O
fever-affected -X- _ O
countries. -X- _ O
Out -X- _ O
of -X- _ O
these -X- _ O
, -X- _ O
35 -X- _ O
sites -X- _ O
were -X- _ O
characterized -X- _ O
based -X- _ O
on -X- _ O
their -X- _ O
capacity -X- _ O
to -X- _ O
hold -X- _ O
Lassa -X- _ B-Intervention
fever -X- _ I-Intervention
vaccine -X- _ I-Intervention
clinical -X- _ I-Intervention
trials. -X- _ I-Intervention
A -X- _ O
total -X- _ O
of -X- _ O
14 -X- _ O
sites -X- _ O
in -X- _ O
4 -X- _ O
countries -X- _ O
were -X- _ O
identified -X- _ O
as -X- _ O
ready -X- _ B-Outcome
to -X- _ I-Outcome
host -X- _ I-Outcome
Lassa -X- _ I-Outcome
fever -X- _ I-Outcome
vaccine -X- _ I-Outcome
trials -X- _ I-Outcome
immediately -X- _ O
or -X- _ O
with -X- _ O
little -X- _ O
support. -X- _ O
CONCLUSION -X- _ O
: -X- _ O
It -X- _ O
is -X- _ O
feasible -X- _ O
to -X- _ O
hold -X- _ O
Lassa -X- _ O
fever -X- _ O
vaccine -X- _ O
trials -X- _ O
in -X- _ O
affected -X- _ O
countries -X- _ O
based -X- _ O
on -X- _ O
the -X- _ O
outcome -X- _ O
of -X- _ O
the -X- _ O
survey. -X- _ O
However -X- _ O
, -X- _ O
the -X- _ O
findings -X- _ O
are -X- _ O
to -X- _ O
be -X- _ O
validated -X- _ O
through -X- _ O
sitesâ€™ -X- _ O
visits. -X- _ O
This -X- _ O
experience -X- _ O
with -X- _ O
a -X- _ O
standardized -X- _ O
and -X- _ O
objective -X- _ O
method -X- _ O
of -X- _ O
the -X- _ O
site -X- _ O
assessment -X- _ O
is -X- _ O
encouraging -X- _ O
, -X- _ O
and -X- _ O
the -X- _ O
site -X- _ O
selection -X- _ O
method -X- _ O
used -X- _ O
can -X- _ O
serve -X- _ O
as -X- _ O
an -X- _ O
orientation -X- _ O
to -X- _ O
sponsors -X- _ O
and -X- _ O
researchers -X- _ O
planning -X- _ O
clinical -X- _ O
trials -X- _ O
in -X- _ O
the -X- _ O
region -X- _ O
. -X- _ O

